Title: Higher Dose of Bevacizumab Safe and Effective as Addition to Colorectal Cancer Chemotherapy: Presented at ASCO-GI
|
|
To print: Select File and then Print from your browser's menu Title: Higher Dose of Bevacizumab Safe and Effective as Addition to Colorectal Cancer Chemotherapy: Presented at ASCO-GI |
|
"Higher Dose of Bevacizumab Safe and Effective as Addition to Colorectal Cancer Chemotherapy: Presented at ASCO-GI" By Roberta Friedman, PhD SAN FRANCISCO, CA -- January 26, 2004 -- Independent confirmation of the safety and efficacy of bevacizumab as an addition to chemotherapy for advanced colorectal cancer, was reported here January 24th at the First Annual Gastrointestinal Cancers Symposium, sponsored jointly by the American Society of Clinical Oncology and other societies. The Phase II trial, which has enrolled 90 patients so far, is testing a 10-mg/kg dose of the agent in combination with irinotecan, 5-fluorouracil (5-FU), and leucovorin. Median survival has not yet been reached, said study investigator Bruce Giantonio, University of Pennsylvania, Philadelphia, who presented the poster. After the trial started, investigators decided to lower the dose of chemotherapy due to reports of deaths on other trials, Dr. Giantonio said in an interview. Despite the lower chemotherapy dose, and the higher dose of antibody used compared to the Genentech-sponsored Phase III study, survival appears to be good, and toxicities manageable, he said. All but four of 47 bleeding events were Grade 1. Rates of Grades 3 and 4 toxicities did not differ between the two chemotherapy doses. Thrombosis occurred 11 times during the trials so far (87 patients provide toxicity results for the report). The dose of antibody is twice that reported earlier, Dr. Giantonio noted. Median follow up of 16.7 months has yielded five complete responses and 35 partial responses. The first 20 patients received 125 mg/m[2 CPT-11, 500 mg/m2 5-FU, and 20 mg/m2 of leucovorin. Starting doses of the first two chemotherapy agents were then reduced to 100 mg/m2 and 400 mg/m2, respectively. Genentech did not fund the study, carried out by the Eastern Cooperative Oncology Group. Dr. Giantonio has served as an advisor to the company and received honoraria. |
|
Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. Go back This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 2009 P\S\L Consulting Group Inc. All rights reserved. |